about
Rhinocerebral mucormycosis treated with 32 gram liposomal amphotericin B and incomplete surgery: a case reportInhibition of amphotericin B (Fungizone) toxicity to cells by egg lecithin-glycocholic acid mixed micellesComparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats.Effects of aggregation and solvent on the toxicity of amphotericin B to human erythrocytesDose-dependent antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion in experimental pulmonary aspergillosisParasitic loads in tissues of mice infected with Trypanosoma cruzi and treated with AmBisome.Liposomal amphotericin B therapy of murine histoplasmosis.Pharmacokinetics of conventional formulation versus fat emulsion formulation of amphotericin B in a group of patients with neutropenia.Amphotericin B: current understanding of mechanisms of action.In vitro models for studying toxicity of antifungal agentsInfluence of diet on experimental toxicity of amphotericin B deoxycholate.Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs.On the one-sided action of amphotericin B on lipid bilayer membranesDaily versus alternate-day regimen of amphotericin B in the treatment of kala-azar: a randomized comparisonNew challenges to the therapy of systemic fungal infections.Driving forces for drug loading in drug carriers.Mechanism of amphotericin B resistance in clinical isolates of Leishmania donovaniThe effect of liposome encapsulation on the pharmacokinetics of recombinant secretory leukocyte protease inhibitor (rSLPI) therapy after local delivery to a guinea pig asthma model.Heat-induced superaggregation of amphotericin B reduces its in vitro toxicity: a new way to improve its therapeutic index.Strategies in prevention of invasive pulmonary aspergillosis in immunosuppressed or neutropenic patientsAerosolized liposomal amphotericin B for treatment of pulmonary and systemic Cryptococcus neoformans infections in mice.Comparative in vitro effects of liposomal amphotericin B, amphotericin B-deoxycholate, and free amphotericin B against fungal strains determined by using MIC and minimal lethal concentration susceptibility studies and time-kill curves.Synthesis of decapeptide of L-aspartic acid and benzyl-L-aspartic acid by solid phase peptide synthesis.Rapid infusion of amphotericin B in dextrose.Intralipid in prophylaxis of amphotericin B nephrotoxicity.Administration of lipid-emulsion versus conventional amphotericin B in patients with neutropenia.Interventional antimicrobial therapy in febrile neutropenic patients. Study Group of the Paul Ehrlich Society for Chemotherapy.Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis.Clinical evaluation of a new lipid-based delivery system for intravenous administration of amphotericin B.Physical characterization and in vivo pharmacokinetic study of self-assembling amphotericin B-loaded lecithin-based mixed polymeric micellesIn search of the amazing technicolour dream coat for amphotericin B.Deleterious effect of serum proteins on the amphotericin B-induced potentiation of cisplatin in human colon cancer cells.Efficacy and safety of fluconazole in the treatment of systemic fungal infections in pediatric patients. Multicentre Study Group.Liposome-based drug delivery to alveolar macrophages.Treatment of deep mycoses with liposomal amphotericin B
P2860
Q24796035-6D62B8A5-6D5C-4C0C-816E-F72A04A5BB3FQ28328856-F178A0A6-F9FA-4661-96B3-CFDD3A885153Q33744215-8EB4BE80-E18D-4D70-B1C1-6568A4686EE7Q33745874-93F5BACE-B7CF-480B-A340-56957852411EQ33751032-3D8F7E74-2B2E-4A1F-BC8B-E6CD5C2F338EQ33955428-20A28E8C-47DA-44D9-AB9A-CEF1F8A0385DQ35117788-F6A0813C-F30E-4E6A-A881-11168147AF15Q35122944-0470CAAA-405B-40FF-90B9-A3BF1684755EQ35247730-F25C1292-276F-4F9B-8327-CC9799677EA4Q35447528-76072081-63B2-4911-B588-ED377279C5B3Q35820200-BF588C4A-99DD-45B9-BFE3-21974A65817EQ35825552-8D18EEAF-C9E8-4113-8C76-1F9672681B32Q36415709-F76E291B-4AB0-4D36-B85C-D8701EA7E3B7Q36794708-5A3F1338-51CE-4590-AB83-31B1C1CE0F84Q38298370-971CD5F2-6013-49A4-AC03-2EB8EAE4A067Q38366771-1C2BCC7B-67BD-4919-B638-B6418B0ED6B7Q39436217-BFD9F416-339F-476C-85AA-D6FAADEA8500Q39529387-BF2E2022-F39F-487D-B323-E71CF4F0E0A3Q39785217-0B4E98C5-43B4-4A46-B32F-DB51F725569EQ39866778-8B3C89E7-D34E-4AD7-A469-65B8C3799E36Q39879675-FE1D92BD-E388-4A16-89F7-DD8F939CC47EQ40085689-159B6592-7B6E-4F70-B288-2886F7596F1EQ40395340-5476873F-95E0-4DB3-B549-D18E2DF10D5AQ40471207-0B9B5D20-0102-4CCA-9744-DA1D6819665CQ40582560-254CD54E-93E9-4C35-8D91-FFBE33E43EB0Q40677144-CE1C3B2B-E5BE-46AE-BEEC-CB05F62379D6Q40694268-A81937FB-7844-40AB-BC7C-AEF5D1079520Q40727940-BAA40E74-65F1-4FFF-B5E4-C49012AD969AQ40730943-57A41E44-9493-4687-B8E5-DF827EA0A4BAQ41915894-48598C55-F819-4F22-BB05-C50E56484F2DQ42544559-EAEFFE2B-B6E2-4582-9547-743F63D922C1Q42590265-2BBC2E71-F285-4B79-B743-764761E7B381Q43473551-4637B6B8-FC9E-44D9-B5DA-E56A8D20A8DDQ44861248-5FC02E61-3C41-43D2-AB4E-225588DD91DDQ57569518-616E9FB6-B739-4B3B-98A4-30EA53409018
P2860
description
1990 nî lūn-bûn
@nan
1990 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1990 թվականի մարտին հրատարակված գիտական հոդված
@hy
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
name
Amphotericin B: delivery systems.
@ast
Amphotericin B: delivery systems.
@en
type
label
Amphotericin B: delivery systems.
@ast
Amphotericin B: delivery systems.
@en
prefLabel
Amphotericin B: delivery systems.
@ast
Amphotericin B: delivery systems.
@en
P2093
P2860
P356
P1476
Amphotericin B: delivery systems.
@en
P2093
G S Kobayashi
J Brajtburg
W G Powderly
P2860
P304
P356
10.1128/AAC.34.3.381
P407
P577
1990-03-01T00:00:00Z